PHOTO
A medic fills a syringe with COVAXIN, an Indian government-backed experimental COVID-19 vaccine, before administering it to a health worker during its trials, at the Gujarat Medical Education and Research Society in Ahmedabad, India, November 26, 2020. Image used for illustrative purpose.
The World Health Organization (WHO) has granted emergency use listing to Covaxin, which is developed by India-based Bharat Biotech, adding to a growing portfolio of vaccines validated by WHO for the prevention of Covid-19.
The WHO Technical Advisory Group has determined that the Covaxin vaccine meets WHO standards for protection against Covid-19, that the benefit of the vaccine far outweighs risks and the vaccine can be used.
The vaccine was also reviewed by WHOs Strategic Advisory Group of Experts on Immunization (SAGE), and recommended use of this vaccine in two doses, with a dose interval of four weeks.
The WHO disclosed that available data on vaccination of pregnant women with the Covaxin vaccine are insufficient to assess vaccine safety or efficacy in pregnancy, adding that it was found to have 78% efficacy against Covid-19 of any severity, 14 or more days after the second dose, and is extremely suitable for low- and middle-income countries due to easy storage requirements.
Copyright 2021 Al Hilal Publishing and Marketing Group Provided by SyndiGate Media Inc. (Syndigate.info).
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an as is and as available basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
